Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: JJINV who wrote (49655)	1/23/2019 2:10:51 PM
From: MFG ENG	1 Recommendation Recommended By JJINV Respond to of 63283

"My comments: The FDA is kind of beating a dead horse here. We know IMMU was not great at preventing contamination" I am not convinced anybody knows that. All conjecture at this point.. we have very little facts. The crucial word in my comment is "was". I KNOW IMMU was not great at preventing contamination as fact because the 483 told me so in clear words in at least 2 of their findings. You just have to be able to interpret the complaints the FDA had which I can because this is my life as a biomedical device manufacturing engineer. My hope is that Pehl and crew have turned this around and uncontrolled contamination will no longer be a specter in subsequent inspections by the FDA. Would really like to see the actually CRL, and a complete response by IMMU magmt. Me too because then I would know the scope of what remediations they are still on the hook for and can better guess at a completion time for that. Is there any way to request this information through the Freedom of Information Act? Sooner than later.